公开(公告)号：US12129236B2

公开(公告)日：2024-10-29

申请号：US17204206

申请日：2021-03-17

申请人： CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Alison E. McGonagle ,  Allan M. Jordan ,  Bohdan Waszkowycz ,  Colin P. Hutton ,  Ian D. Waddell ,  James R. Hitchin ,  Kate M. Smith ,  Niall M. Hamilton

IPC分类号： C07D235/26 ,  A61P35/00 ,  C07D307/85 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14

CPC分类号： C07D235/26 ,  A61P35/00 ,  C07D307/85 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14

摘要： The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

公开(公告)号：US20240287020A1

公开(公告)日：2024-08-29

申请号：US18614086

申请日：2024-03-22

申请人： THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

发明人： Armando CÁZARES-KÖRNER ,  Thomas HELLEDAY ,  Torkild VISNES ,  Olov WALLNER ,  Tobias KOOLMEISTER

IPC分类号： C07D401/04 ,  A61K45/06 ,  A61P35/00 ,  C07D235/26 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

CPC分类号： C07D401/04 ,  A61P35/00 ,  C07D235/26 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  A61K45/06

摘要： There is provided herein a compound of formula I




or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3, and n have meanings provided in the description.

公开(公告)号：US20240270701A1

公开(公告)日：2024-08-15

申请号：US18694362

申请日：2022-09-22

申请人： Curasen Therapeutics, Inc.

发明人： Jiaxin Yu ,  Anthony P. Ford ,  Wei Chen

IPC分类号： C07D241/42 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/417 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/47 ,  A61K31/498 ,  A61K31/517 ,  C07D209/34 ,  C07D213/38 ,  C07D213/61 ,  C07D213/73 ,  C07D215/14 ,  C07D215/233 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D237/20 ,  C07D239/42 ,  C07D239/74 ,  C07D277/40 ,  C07D277/68 ,  C07D471/04

CPC分类号： C07D241/42 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/417 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/47 ,  A61K31/498 ,  A61K31/517 ,  C07D209/34 ,  C07D213/38 ,  C07D213/61 ,  C07D213/73 ,  C07D215/14 ,  C07D215/233 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D237/20 ,  C07D239/42 ,  C07D239/74 ,  C07D277/40 ,  C07D277/68 ,  C07D471/04

摘要： The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with modulation of beta-adrenergic receptors. In addition, the disclosure provides methods of using the compounds described herein for the treatment of diseases associated with an adrenergic receptor, including but not limited to neurodegenerative diseases and disorders.

公开(公告)号：US20240199555A1

公开(公告)日：2024-06-20

申请号：US18551361

申请日：2022-03-18

申请人： Centre National de la Recherche Scientifique ,  Université d'Orléans

发明人： Séverine MORISSET-LOPEZ ,  Franck SUZENET ,  Gérald GUILLAUMET ,  Emmanuel DEAU ,  Elodie ROBIN ,  Chayma EL KHAMLICHI ,  Flora REVERCHON-ASSADI ,  Nadège HERVOUET-COSTE ,  Fahima MADOURI ,  Marie-Aude HIEBEL ,  Julie LE-BESCONT

IPC分类号： C07D235/26 ,  A61K31/496 ,  A61P29/00 ,  C07D233/36 ,  C07D401/12 ,  C07D403/12 ,  C07D487/10

CPC分类号： C07D235/26 ,  A61K31/496 ,  A61P29/00 ,  C07D233/36 ,  C07D401/12 ,  C07D403/12 ,  C07D487/10

摘要： The present invention relates to a compound having the following formula (1)






wherein:

R and R′ are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group;
R2 is selected from the group consisting of: H, (C1-C6)alkyl group, halo(C1-C6)alkyl group, aryl, and heteroaryl;
A1 is a linker;
R″ is either a group (A-1) or a group (A-2)


for use in the treatment of a brain disorder involving modified 5-HT7R-mediated signaling, especially for use in the treatment of pain or inflammation or in the treatment of multiple sclerosis, or for use to induce hypothermia.

公开(公告)号：US20240083903A1

公开(公告)日：2024-03-14

申请号：US18264468

申请日：2022-02-15

申请人： Jongwon Lim ,  Vladimir Simov ,  Brandon A. Vara ,  Charles S. Yeung ,  Sebastian E. Schneider ,  Erin F. DiMauro ,  Merck Sharp& Dohme LLC

发明人： Jongwon Lim ,  Vladimir Simov ,  Brandon A. Vara ,  Charles S. Yeung ,  Sebastian E. Schneider ,  Erin F. DiMauro

IPC分类号： C07D487/04 ,  A61P35/00 ,  C07D209/34 ,  C07D215/20 ,  C07D217/04 ,  C07D231/56 ,  C07D235/24 ,  C07D235/26 ,  C07D237/28 ,  C07D239/84 ,  C07D263/57 ,  C07D265/36 ,  C07D277/66 ,  C07D317/56 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D487/04 ,  A61P35/00 ,  C07D209/34 ,  C07D215/20 ,  C07D217/04 ,  C07D231/56 ,  C07D235/24 ,  C07D235/26 ,  C07D237/28 ,  C07D239/84 ,  C07D263/57 ,  C07D265/36 ,  C07D277/66 ,  C07D317/56 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

摘要： The present invention is directed to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising them and methods of using such compounds or pharmaceutical salts thereof.

公开(公告)号：US20230295095A1

公开(公告)日：2023-09-21

申请号：US18011459

申请日：2021-06-18

申请人： KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Ae Nim PAE ,  Yun Kyung KIM ,  Sang Min LIM ,  Sungsu LIM ,  Haeun LEE ,  Woo Seung SON ,  Hye Yeon LEE

IPC分类号： C07D217/24 ,  C07D235/26 ,  C07D263/58 ,  C07D277/68 ,  C07D215/227 ,  C07D471/04

CPC分类号： C07D217/24 ,  C07D235/26 ,  C07D263/58 ,  C07D277/68 ,  C07D215/227 ,  C07D471/04

摘要： Provided are novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and uses thereof.

公开(公告)号：US20230192626A1

公开(公告)日：2023-06-22

申请号：US17999408

申请日：2021-05-26

申请人： Baylor College of Medicine

发明人： Jin Wang ,  Hui Zheng ,  Lisheng Deng ,  Anamitra Ghosh

IPC分类号： C07D235/18 ,  C07D235/14 ,  C07D235/30 ,  C07D235/26 ,  C07D235/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D413/10 ,  C07D401/10 ,  C07D403/10 ,  C07D401/12 ,  C07D403/12 ,  C07D487/04 ,  C07D413/12 ,  C07D471/04 ,  C07D473/40 ,  C07D473/34 ,  A61K45/06

CPC分类号： C07D235/18 ,  C07D235/14 ,  C07D235/30 ,  C07D235/26 ,  C07D235/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D413/10 ,  C07D401/10 ,  C07D403/10 ,  C07D401/12 ,  C07D403/12 ,  C07D487/04 ,  C07D413/12 ,  C07D471/04 ,  C07D473/40 ,  C07D473/34 ,  A61K45/06

摘要： Novel soluble epoxide hydrolase (sEH) inhibitors are provided, along with methods for their use. The soluble epoxide hydrolase inhibitors are useful in treating and/or preventing sEH-related related diseases, such as Alzheimer's disease and inflammation. Also provided are methods for inhibiting soluble epoxide hydrolase in a cell using the compounds and compositions described herein.

公开(公告)号：US20230045357A1

公开(公告)日：2023-02-09

申请号：US17861809

申请日：2022-07-11

申请人： Université de Montréal ,  Bristol-Myers Squibb Company

发明人： Eldon Scott PRIESTLEY ,  Samuel Kaye REZNIK ,  Edward H. RUEDIGER ,  James R. GILLARD ,  Oz Scott HALPERN ,  Wen JIANG ,  Jeremy RICHTER ,  Rejean RUEL ,  Sasmita TRIPATHY ,  Wu YANG ,  Xiaojun ZHANG

IPC分类号： C07D401/14 ,  C07D401/10 ,  C07D235/26 ,  C07D403/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D257/04 ,  C07D417/14 ,  C07D405/14 ,  C07D233/90 ,  C07D498/10 ,  C07D413/14 ,  A61P9/04 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  C07D239/20 ,  C07D271/07

摘要： The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

公开(公告)号：US20220151991A1

公开(公告)日：2022-05-19

申请号：US17439148

申请日：2020-03-13

申请人： Board of Regents, The University of Texas System ,  Board of Trustees of the University of Arkansas

发明人： Zamal AHMED ,  John A. TAINER ,  Darin E. JONES

IPC分类号： A61K31/404 ,  C07D209/34 ,  C07D409/12 ,  C07D405/12 ,  A61K31/4184 ,  C07D235/26 ,  A61K31/5377 ,  C07D235/28 ,  A61K31/423 ,  C07D263/58 ,  A61P35/00

摘要： The present disclosure compounds of the formula (I-A) or (I), wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods for the use of said compounds and/or pharmaceutical compositions, such as in the treatment of cancer. The present disclosure also provides methods for the use of compounds of the formula (III), wherein the variables are defined herein.

公开(公告)号：US11319231B2

公开(公告)日：2022-05-03

申请号：US16611909

申请日：2018-07-02

申请人： Dow Global Technologies LLC

发明人： Kaylie L. Young ,  Clark H. Cummins ,  William C. Glover ,  Robert David Grigg

IPC分类号： C02F5/12 ,  C07D235/22 ,  C07D235/24 ,  C07D235/26 ,  C07D235/28 ,  C07D271/12 ,  C07D285/14 ,  C08F34/00 ,  C08F134/00 ,  C08F234/00 ,  C08F220/06 ,  C08F220/56 ,  C08F220/58 ,  B01D65/08 ,  C02F1/00 ,  C09K11/06 ,  C02F5/10

摘要： The present invention relates to a fluorescently-tagged (co)polymer and use thereof useful as a scale inhibitor in industrial water systems. Said (co)polymer comprises a (i) reactive fluorescent compound selected from a benzodiazole compound (ii) at least one monoethylenically unsaturated acid monomer, and (iii) optionally, at least one monoethylenically unsaturated acid-free monomer.